Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $41.25.

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research report on Tuesday, October 14th. Citigroup assumed coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They set an “outperform” rating for the company. Zacks Research raised Assembly Biosciences to a “hold” rating in a research report on Tuesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, October 8th. Finally, JMP Securities assumed coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They issued a “market outperform” rating and a $38.00 price objective for the company.

Assembly Biosciences Stock Performance

Shares of ASMB opened at $29.45 on Friday. Assembly Biosciences has a 52 week low of $7.75 and a 52 week high of $30.20. The stock has a market capitalization of $225.88 million, a price-to-earnings ratio of -5.28 and a beta of 0.60. The stock has a fifty day moving average of $24.85 and a 200-day moving average of $18.37.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.73) by $0.40. The business had revenue of $9.63 million during the quarter, compared to analyst estimates of $5.30 million. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%. As a group, equities analysts forecast that Assembly Biosciences will post -6.87 EPS for the current year.

Institutional Trading of Assembly Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASMB. Ellsworth Advisors LLC bought a new stake in Assembly Biosciences during the 3rd quarter worth approximately $852,000. American Century Companies Inc. bought a new stake in Assembly Biosciences during the 1st quarter worth approximately $113,000. Acadian Asset Management LLC increased its holdings in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 6,823 shares in the last quarter. Palumbo Wealth Management LLC increased its holdings in Assembly Biosciences by 57.4% during the 1st quarter. Palumbo Wealth Management LLC now owns 17,986 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 6,559 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Assembly Biosciences by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 3,312 shares in the last quarter. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.